Drug Trial Radar · NCT06475495
Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
13
Planned (sponsor's estimate)
Start
Dec 4, 2024
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Charite University, Berlin, GermanyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kyverna Therapeutics
- First posted
- Jun 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this phase I/II clinical trial is to compare B-cell depletion by rituximab and anti-CD 19 CAR-T therapy in patients with rheumatoid arthritis. The main questions it aims to answer are: * To assess the safety of anti-CD19 CAR T cell therapy in subjects with active, ACPA positive and treatment refractory RA (Phase-I) * To assess the safety of anti-CD19 CAR T cell therapy and of rituximab in subjects with active, ACPA positive and treatment refractory RA (Phase-II) * To assess ACPA seroconversion after anti-CD19 CAR T cell or rituximab therapy in subjects with active, ACPA positive and treatment refractory RA (Phase-II) Participants in the test-arm will receive a single dose of KYV-101 i.v., an autologous fully-human anti-CD19 CAR T-cell immunotherapy. In the comparator group patients will receive 2x1 g Rituximab i.v. Follow-up time (both arms) is 52 weeks with regular visits at the site.
Conditions
- Rheumatoid Arthritis
Interventions
KYV101Drug
an autologous fully-human anti-CD19 CAR T-cell immunotherapy
Rituximab (active comparator)Drug
anti CD20 monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Phase I (1) SafetyTime frame: up to week 52
- Safety Phase I (2) SafetyTime frame: up to 52 weeks
- Safety Phase I (3) SafetyTime frame: up to 52 weeks
- Safety Phase I (4) SafetyTime frame: up to 52 weeks
- Efficacy Phase IITime frame: visit week 16
- Safety Phase II (1)Time frame: up to 52 weeks
- Safety Phase II (2)Time frame: up to 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.